A study led by Susan G. Komen Brinker Award winner Carlos Caldas found that there may be a way to predict treatment response in breast cancer patients even before treatment begins. Results will be presented at the 2021 San Antonio Breast Cancer Symposium Dec. 7-10.
The use of multigene sequencing as a therapeutic decision tool improved outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), according to results from the SAFIR02-BREAST trial.
The investigational oral selective estrogen receptor degrader elacestrant significantly decreased the risk of death or disease progression and increased progression-free survival compared with standard-of-care endocrine therapy for postmenopausal patients with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancers that progressed on prior endocrine and targeted therapies, according to results from the phase III EMERALD trial.
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus Ibrance (palbociclib), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to Faslodex (fulvestrant) plus Ibrance, according to results from the phase III PADA-1 clinical trial.
Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was the strongest predictor of lymphedema development, according to results presented at the San Antonio Breast Cancer Symposium.
Results from the registration-enabling EXPLORER and PATHFINDER trials of Ayvakit (avapritinib) highlighted its robust efficacy and safety datasets in advanced systemic mastocytosis.
Yale Cancer Center researchers have revealed the structure of anaplastic lymphoma kinase—a molecule that drives several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors—opening new paths for cancer treatment.
IMGN853 (mirvetuximab soravtansine) yielded positive top-line data in the pivotal phase III SORAYA trial evaluating the safety and efficacy of the monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).
Suzanne M. Miller, a professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, developed a special edition of Translational Behavioral Medicine that summarizes several major lines of cancer prevention and control research and outlines future directions.
The American Lung Association’s 4th annual “State of Lung Cancer” report showed that the lung cancer five-year survival rate increased 14.5% nationally to 23.7% yet remains significantly lower among communities of color.
